Hyperglycemia enhances coagulation and reduces neutrophil degranulation, whereas hyperinsulinemia inhibits fibrinolysis during human endotoxemia

Blood

Volumn 112, Issue 1, 2008, Pages 82-89

  Stegenga, Michiel E ^a   Van Der Crabben, Saskia N ^a   Blümer, Regje M E ^a   Levi, Marcel ^a   Meijers, Joost C M ^a   Serlie, Mireille J ^a   Tanck, Michael W T ^a   Sauerwein, Hans P ^a   Van Der Poll, Tom ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ELASTASE; ESCHERICHIA COLI ENDOTOXIN; GLUCOSE; INSULIN; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBIN ANTITHROMBIN COMPLEX; THROMBOPLASTIN; TUMOR NECROSIS FACTOR ALPHA; AUTACOID; CYTOKINE; ENDOTOXIN;

ADULT; ARTICLE; BLOOD CLOTTING; CELL ACTIVATION; CELL FUNCTION; CYTOKINE RELEASE; ENDOTHELIUM; ENDOTHELIUM CELL; ENDOTOXEMIA; ENZYME BLOOD LEVEL; FIBRINOLYSIS; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; HYPERGLYCEMIA; HYPERINSULINEMIA; INFLAMMATION; INSULIN BLOOD LEVEL; LEUKOCYTE ACTIVATION; MALE; NEUTROPHIL; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEGRANULATION; GLUCOSE CLAMP TECHNIQUE; HYPERINSULINISM; IMMUNOLOGY; INNATE IMMUNITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL;

ADULT; BLOOD COAGULATION; CELL DEGRANULATION; CYTOKINES; DIABETES MELLITUS, TYPE 2; ENDOTHELIAL CELLS; ENDOTOXEMIA; ENDOTOXINS; FIBRINOLYSIS; GLUCOSE CLAMP TECHNIQUE; HUMANS; HYPERGLYCEMIA; HYPERINSULINISM; IMMUNITY, NATURAL; INFLAMMATION MEDIATORS; MALE; NEUTROPHILS;

EID: 47249138753     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-11-121723     Document Type: Article

References (37)

1. Carr ME. Diabetes mellitus: a hypercoagulable state. J Diabetes Complications. 2001; 15:44-54.
2. Calles-Escandon J, Garcia-Rubi E. Mirza S, Mortensen A. Type 2 diabetes: one disease, multiple cardiovascular risk factors. Coron Artery Dis. 1999;10:23-30.
3. Shah BR, Hux JE. Quantifying the risk of infectious diseases for people with diabetes. Diabetes Care. 2003;26:510-513.
4. Kado S, Nagase T Nagata N. Circulating levels of interleukin-6, its soluble receptor and interleukin-6/interleukin-6 receptor complexes in patients with type 2 diabetes mellitus. Acta Diabetol. 1999; 36:67-72.
5. Pickup JC, Chusney GD, Thomas SM, Burt D. Plasma interleukin-6. tumour necrosis factor alpha and blood cytokine production in type 2 diabetes. Life Sci. 2000;67:291-300.
6. Marhoffer W, Stein M, Maeser E, Federlin K. Impairment of polymorphonuclear leukocyte function and metabolic control of diabetes. Diabetes Care. 1992;15:256-260.
7. Stegenga ME, van der Crabben SN, Levi M, et al. Hyperglycemia stimulates coagulation, whereas hyperinsulinernia impairs fibrinolysis in healthy humans. Diabetes. 2006;55:1807-1812.
8. Levi M, van der Poll T, Buller HR. Bidirectional relation between inflammation and coagulation. Circulation. 2004;109:2698-2704.
9. van den Berghe G, Wouters P, Weekers F. et al. Intensive insulin therapy in the critically ill patients. N EnglJ Med. 2001;345:1359-1367.
10. Van den Berghe G, Wilmer A, Hermans G, et al. Intensive insulin therapy in the medical ICU. N Engl J Med. 2006;354:449-461.
11. Lowry SF Human endotoxemia: a model for mechanistic insight and therapeutic targeting. Shock. 2005;24(suppl 1):94-100.
12. Schultz MJ, Speelman P, Hack CE, Buurman WA, van Deventer SJ, van Der Poll T Intravenous infusion of erythromycin inhibits CXC chemokine production, but augments neutrophil degranulation in whole blood stimulated with Streptococcus pneumoniae. J Antimicrob Chemother. 2000;46:235-240.
13. Bresser P, Out TA, van Alphen L, Jansen HM, Lutter R. Airway inflammation in nonobstructive and obstructive chronic bronchitis with chronic haemophilus influenzae airway infection: comparison with noninfected patients with chronic obstructive pulmonary disease. Am J Respir Grit Care Med. 2000;162:947-952.
14. Verheijen JH, Chang GT, Kluft C. Evidence for the occurrence of a fast-acting inhibitor for tissuetype plasminogen activator in human plasma. Thromb Haemost. 1984;51:392-395.
15. Verheijen JH, Mullaart E, Chang GT Kluft C, Wijngaards G. Asimple, sensitive spectrophotometric assay for extrinsic (tissue-type) plasminogen activator applicable to measurements in plasma. Thromb Haemost. 1982;48:266-269.
16. Turina M, Fry DE, Polk HC Jr. Acute hyperglycemia and the innate immune system: clinical, cellular, and molecular aspects. Crit Care Med. 2005; 33:1624-1633.
17. Pham CT. Neutrophil serine proteases: specific regulators of inflammation. Nat Rev Immunol. 2006;6:541-550.
18. Shurtz-Swirski R, Sela S, Herskovits AT, et al. Involvement of peripheral polymorphonuclear leukocytes in oxidative stress and inflammation in type 2 diabetic patients. Diabetes Care. 2001;24:104-110.
19. Shim WS, Kim HJ, Kang ES, et al. The association of total and differential white blood cell count with metabolic syndrome in type 2 diabetic patients. Diabetes Res Clin Pract. 2006;73:284-291.
20. Ling PR, Smith RJ, Bistrian BR. Hyperglycemia enhances the cytokine production and oxidative responses to a low but not high dose of endotoxin in rats. Crit Care Med. 2005;33:1084-1089.
21. Soop M, Duxbury H, Agwunobi AO, et al. Euglycemic hyperinsulinemia augments the cytokine and endocrine responses to endotoxin in humans. Am J Physiol Endocrinol Metab. 2002;282: E1276-E1285.
22. Krogh-Madsen R, Moller K, Dela F, Kronborg G, Jauffred S. Pedersen BK. Effect of hyperglycemia and hyperinsulinemia on the response of IL-6, TNF-alpha, and FFAs to low-dose endotoxemia in humans. Am J Physiol Endocrinol Metab. 2004; 286:E766-E772.
23. Altannavch TS, Roubalova K, Kucera P, Andel M. Effect of high glucose concentrations on expression of ELAM-1, VCAM-1 and ICAM-1 in HUVEC with and without cytokine activation. Physiol Res. 2004;53:77-82.
24. Bluher M, Linger R, Rassoul F, Richter V, Paschke R. Relation between glycaemic control, hyperinsulinaemia and plasma concentrations of soluble adhesion molecules in patients with impaired glucose tolerance or Type II diabetes. Diabetologia. 2002;45:210-216.
25. Ceriello A, Quagliaro L, Piconi L, et al. Effect of postprandial hypertriglyceridemia and hyperglycemia on circulating adhesion molecules and oxidative stress generation and the possible role of simvastatin treatment. Diabetes. 2004:53:701-710.
26. Sampson M, Davies I, Gavrilovic J, et al. Plasma matrix metalloproteinases, low density lipoprotein oxidisability and soluble adhesion molecules after a glucose load in Type 2 diabetes. Gardiovasc Diabetol (http://www.cardiab.com). 2004;3:7.
27. van der Poll T, Coyle SM, Levi M, et al. Effect of a recombinant dimeric tumor necrosis factor receptor on inflammatory responses to intravenous endotoxin in normal humans. Blood. 1997;89:3727-3734.
28. Reinhart K, Bayer O, Brunkhorst F Meisner M. Markers of endothelial damage in organ dysfunction and sepsis. Crit Care Med. 2002;30:S302-S312.
29. Samad F, Pandey M, Bell PA, Loskutoff DJ. Insulin continues to induce plasminogen activator inhibitor 1 gene expression in insulin-resistant mice and adipocytes. Mol Med. 2000;6:680-692.
30. Meigs JB, Mittleman MA, Nathan DM. et al. Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study. JAMA. 2000;283:221-228.
31. Landin K, Tengborn L, Chmielewska J, von Schenck H, Smith U. The acute effect of insulin on tissue plasminogen activator and plasminogen activator inhibitor in man. Thromb Haemost. 1991;65:130-133.
32. Vuorinen-Markkola H, Puhakainen I, Yki-Jarvinen H. No evidence for short-term regulation of plasminogen activator inhibitor activity by insulin in man. Thromb Haemost. 1992;67:117-120.
33. Henkel E, Gallo S, Siegert G, Koehler C, Hanefeld M. Glucagon as a determinant of fibrinolytic activity in men with different stages of glucose tolerance: impact of glucagon on fibrinolysis. Blood Coagul Fibrinolysis. 2007;18:327-334.
34. de Jonge E, Dekkers PE, Creasey AA, et al. Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia. Blood. 2000;95:1124-1129.
35. Gando S. Disseminated intravascular coagulation in trauma patients. Semin Thromb Hemost. 2001; 27:585-592.
36. Aras O, Shet A, Bach RR, et al. Induction of microparticle-and cell-associated intravascular tissue factor in human endotoxemia. Blood. 2004; 103:4545-4553.
37. Umpierrez GE, Isaacs SD, Bazargan N. You X, Thaler LM, Kitabchi AE. Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes. J Clin Endocrinol Metab. 2002;87:978-982.